학술논문
Elevated plasma level of the glycolysis byproduct methylglyoxal on admission is an independent biomarker of mortality in ICU COVID-19 patients
Document Type
article
Author
Fadhel A. Alomar; Marai N. Alshakhs; Salah Abohelaika; Hassan M. Almarzouk; Mohammed Almualim; Amein K. Al-Ali; Fahad Al-Muhanna; Mohammed F. Alomar; Mousa J. Alhaddad; Mohammed S. Almulaify; Faisal S. Alessa; Ahmed S. Alsalman; Ahmed Alaswad; Sean R. Bidasee; Hassan A. Alsaad; Rudaynah A. Alali; Mona H. AlSheikh; Mohammed S. Akhtar; Mohammed Al Mohaini; Abdulkhaliq J. Alsalman; Hussain Alturaifi; Keshore R. Bidasee
Source
Scientific Reports, Vol 12, Iss 1, Pp 1-22 (2022)
Subject
Language
English
ISSN
2045-2322
Abstract
Abstract Biomarkers to identify ICU COVID-19 patients at high risk for mortality are urgently needed for therapeutic care and management. Here we found plasma levels of the glycolysis byproduct methylglyoxal (MG) were 4.4-fold higher in ICU patients upon admission that later died (n = 33), and 1.7-fold higher in ICU patients that survived (n = 32),compared to uninfected controls (n = 30). The increased MG in patients that died correlated inversely with the levels of the MG-degrading enzyme glyoxalase-1 (r 2 = − 0.50), and its co-factor glutathione (r 2 = − 0.63), and positively with monocytes (r 2 = 0.29). The inflammation markers, SSAO (r 2 = 0.52), TNF-α (r 2 = 0.41), IL-1β (r 2 = 0.25), CRP (r 2 = 0.26) also correlated positively with MG. Logistic regression analysis provides evidence of a significant relationship between the elevated MG upon admission into ICU and death (P